𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Inhibition of growth of MDA-MB-231 human breast cancer xenografts in nude mice by bombesin/gastrin-releasing peptide (GRP) antagonists RC-3940-II and RC-3095

✍ Scribed by M Miyazaki; N Lamharzi; A.V Schally; G Halmos; K Szepeshazi; K Groot; R.Z Cai

Book ID
117664188
Publisher
Elsevier Science
Year
1998
Tongue
English
Weight
181 KB
Volume
34
Category
Article
ISSN
0959-8049

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Inhibition of growth of MDA-MB-468 estro
Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II
✍ Zsuzsanna Kahán; Baodong Sun; Andrew V. Schally; José M. Arencibia; Ren-Zhi Cai; 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 133 KB

## BACKGROUND. The growth of breast carcinoma is promoted by autocrine growth factors such as the bombesin (BN)-like peptides and epidermal growth factor (EGF). The stimulatory action of BN-like peptides can be blocked by the use of BN/gastrin-releasing peptide (GRP) antagonists. ## METHODS. The

Effect of somatostatin analog RC-160 and
Effect of somatostatin analog RC-160 and bombesin/gastrin releasing peptide antagonist RC-3095 on growth of PC-3 human prostate-cancer xenografts in nude mice
✍ Jacek Pinski; Andrew V. Schally; Gabor Halmos; Karoly Szepeshazi 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 French ⚖ 679 KB

## Abstract Nude mice bearing xenografts of the androgen‐independent human prostate‐cancer cell line PC‐3 were treated for 4 weeks with somatostatin analog RC‐160, bombesin/gastrin‐releasing peptide (GRP) antagonist (RC‐3095), or the combination of both peptides. In the first experiment, treatment

Inhibition of growth of MKN45 human gast
Inhibition of growth of MKN45 human gastric-carcinoma xenografts in nude mice by treatment with bombesin/gastrin-releasing-peptide antagonist (RC-3095) and somatostatin analogue RC-160
✍ Jucek Pinski; Gabor Halmos; Tetsu Yano; Karoly Szepeshazi; Yunfeng Qin; Tibor Er 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 French ⚖ 853 KB

## Abstract Nude mice bearing xenografts of the gastrin‐responsive human gastric carcinoma MKN45 cell line were treated for 4 to 5 weeks with bombesin/gastrin‐releasing‐peptide(GRP) antagonist (RC‐3095), somatostatin analogues RC‐160 and SMS 201‐995, or the combination of RC‐3095 and RC‐160. Tumor

Bombesin/gastrin-releasing peptide antag
Bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II inhibit tumor growth and decrease the levels and mRNA expression of epidermal growth factor receptors in H-69 small cell lung carcinoma
✍ Miklós Koppán; Gábor Halmos; José M. Arencibia; Najib Lamharzi; Andrew V. Schall 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB 👁 1 views

## BACKGROUND. Antagonists of bombesin/gastrin-releasing peptide (BN/GRP) have been developed to block the autocrine stimulatory effect of BN/GRP on tumors such as small cell lung carcinoma (SCLC). Although several studies have addressed the intracellular events that follow the formation of the re

Luteinizing hormone-releasing hormone an
Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice
✍ Jungwirth, Andreas; Galvan, Georg; Pinski, Jacek; Halmos, Gabor; Szepeshazi, Kar 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB 👁 2 views

## Background: Hormones like bombesin (bn)/gastrin-releasing peptide (grp) and luteinizing hormone-releasing hormone (lh-rh) and growth factors such as epidermal growth factor (egf) might be involved in the relapse of prostate cancer under androgen ablation therapy. interference with receptors for